Axsome Therapeutics Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Founder leadership rather than any controlling block defines Axsome's ownership: Herriot Tabuteau founded the company in 2012, remains chief executive and board chair, and holds about 4 percent of the shares, while institutions, Vanguard, BlackRock, and the biotech-focused Perceptive Advisors and Farallon, own the bulk. That founder continuity matters because Axsome has reached a delicate inflection, evolving from a clinical-stage developer into a commercial biopharmaceutical company selling approved medicines, and Tabuteau's strategy shapes how it navigates that transition. The company now markets AUVELITY for major depressive disorder and, following a 2026 approval, Alzheimer's disease agitation, SUNOSI for excessive daytime sleepiness, and SYMBRAVO for migraine, generating about 638 million dollars of 2025 revenue while continuing to invest heavily in launches and a pipeline of investigational CNS treatments. Its approach blends internal development with targeted asset acquisitions and licenses, preserving independence while committing future milestone payments and commercial resources across a widening neuroscience portfolio. Shareholders are backing management's ability to commercialize these medicines successfully in large, competitive neuropsychiatric markets, advance the pipeline, and eventually convert a growing top line into profitability. The equity's value rests on the commercial trajectory of the approved products and the promise of the pipeline, executed by a founder-led team, rather than on any established earnings or ownership protection.
Direct Owners
Institutional Shareholders
Shareholder Analysis
With about 638 million dollars of 2025 revenue and a portfolio of approved medicines, Axsome sits between the binary risk of a clinical-stage biotech and the earnings profile of an established pharmaceutical company, and its investment case turns on commercial execution and pipeline value. The appeal is genuine: Axsome has successfully brought AUVELITY to market for major depressive disorder and, in 2026, secured its approval for Alzheimer's disease agitation, a large underserved indication, alongside SUNOSI and the migraine treatment SYMBRAVO, giving it a growing revenue base in sizable neuropsychiatric markets, and its pipeline of investigational treatments for narcolepsy, fibromyalgia and epilepsy offers further optionality, all directed by an aligned founder-chief-executive. Weighing against this are the risks that accompany a company still scaling commercially: heavy investment in product launches and development means profitability is not yet secure, its medicines face competition from far larger companies such as Otsuka, Johnson and Johnson and Jazz in overlapping CNS markets, commercial uptake of newer launches must prove out, and pipeline candidates carry the ever-present risk of clinical or regulatory failure. The company has also committed substantial future milestone payments through its asset acquisitions. The equity offers exposure to a founder-led neuroscience company at the promising but unproven stage of commercial scale-up, and its returns depend on driving adoption of its approved medicines, advancing the pipeline, and converting revenue growth into sustainable profitability against well-resourced competitors.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| AUVELITY | Brand | Medicine for major depressive disorder and Alzheimer's agitation |
| SUNOSI | Brand | Medicine for excessive daytime sleepiness |
| SYMBRAVO | Brand | Medicine for acute migraine treatment |
| AXS-Twelve | Program | Investigational narcolepsy treatment |
| AXS-Fourteen | Program | Investigational fibromyalgia treatment |
| AXS-Seventeen | Program | Investigational epilepsy treatment |
Portfolio Analysis
Axsome's competitive identity rests on a focused portfolio of differentiated central-nervous-system medicines rather than on any consumer brand, with each product targeting a specific neuropsychiatric or neurological need. Its lead medicine AUVELITY treats major depressive disorder and, following a 2026 approval, Alzheimer's disease agitation, addressing large markets where a novel mechanism offers differentiation; SUNOSI treats excessive daytime sleepiness; and SYMBRAVO, launched in 2025, addresses acute migraine, together forming a commercial franchise concentrated in CNS conditions. Behind these approved products sits a pipeline of investigational candidates for narcolepsy, fibromyalgia and epilepsy, extending the company's reach across neuroscience. The strategy is to build a specialized CNS pharmaceutical company with a differentiated portfolio addressing conditions with significant unmet need and large patient populations, combining internally developed and acquired assets under one commercial and clinical organization focused entirely on the brain and nervous system. Axsome's competitive strength lies in this focus and differentiation: rather than compete broadly, it targets specific CNS indications where its medicines offer novel mechanisms or improved profiles, cultivating expertise in neuroscience commercialization. The durability of that identity depends on the clinical differentiation of its products holding up in the market and on the company continuing to advance and acquire assets that reinforce its specialized neuroscience franchise against far larger competitors with their own CNS portfolios.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Axsome Therapeutics ★ | N/A | $639M FY2025 | Commercial central nervous system biopharmaceutical company |
| Otsuka Pharmaceutical | N/A | $15B FY2025 | Global neuroscience company with Rexulti |
| Johnson and Johnson | N/A | $94B FY2025 | Global pharmaceutical company with Spravato |
| Jazz Pharmaceuticals | N/A | $4.2B FY2025 | Neuroscience and oncology biopharmaceutical company |
| Intra-Cellular Therapies | N/A | N/A | Johnson and Johnson-owned neuroscience company |
Competitive Analysis
Axsome competes in central-nervous-system pharmaceuticals, a therapeutic area of large markets and significant unmet need but also intense competition from far larger companies. In its core indications it faces formidable rivals: Otsuka markets neuroscience products including Rexulti in areas overlapping Axsome's, Johnson and Johnson competes in depression with Spravato and, through its acquisition of Intra-Cellular, in broader neuroscience, and Jazz Pharmaceuticals, from which Axsome acquired SUNOSI, remains a neuroscience competitor. Axsome's competitive footing rests on the differentiation of its medicines, AUVELITY's novel mechanism in depression and its 2026 approval in Alzheimer's agitation, an area of high unmet need, along with SUNOSI and SYMBRAVO, and on its focus and agility as a specialized neuroscience company able to concentrate its commercial and development resources entirely on CNS conditions. The pressures it faces are considerable: its competitors possess vastly greater scale, resources and established sales forces, commercial uptake of its newer products must prove out against entrenched alternatives, and pipeline candidates must succeed clinically to sustain growth. Axsome competes as a focused, differentiated neuroscience company against much larger generalists, and its competitive prospects depend on the clinical and commercial differentiation of its portfolio, particularly the expansion of AUVELITY into Alzheimer's agitation and the uptake of its newer launches, translating specialized focus and novel mechanisms into durable market positions in CNS indications where the largest pharmaceutical companies also compete.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| SUNOSI rights | $53M upfront | 2022 | Added a commercial sleep medicine from Jazz Pharmaceuticals |
| Baergic Bio | N/A | 2025 | Added AXS-Seventeen for epilepsy |
| Deuterated bupropion rights | Up to $523M milestones | 2025 | Added a next-generation central nervous system asset |
| Pfizer reboxetine rights | N/A | 2020 | Added the asset developed as AXS-Twelve |
Acquisitions Analysis
Axsome has deliberately combined internal development with targeted asset acquisitions and licenses rather than pursuing corporate mergers, a model that has broadened its portfolio while preserving independence. The most significant purchase was the 2022 acquisition of rights to SUNOSI from Jazz Pharmaceuticals for 53 million dollars upfront, which added an approved, commercial sleep medicine and helped establish Axsome's commercial capabilities, complemented by the earlier licensing of Pfizer's reboxetine, developed as the pipeline candidate AXS-Twelve. It has continued this approach, acquiring Baergic Bio in 2025 to add an epilepsy candidate and licensing deuterated bupropion rights from DeuteRx that same year in a deal carrying up to 523 million dollars of potential milestones, adding a next-generation CNS asset. This strategy of buying and licensing assets rather than whole companies lets Axsome expand its neuroscience portfolio selectively while keeping its corporate independence, but it commits substantial future milestone payments and demands commercial and development resources across a widening set of programs. Value creation therefore comes from a blend of internal innovation and disciplined asset acquisition, both aimed at building a specialized CNS portfolio, and the company's future depends on successfully developing and commercializing the assets it has assembled through this model, converting acquired and internally developed candidates into approved, revenue-generating medicines while managing the milestone obligations that its acquisitive licensing has created.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Axsome's corporate structure has been shaped by internal development and asset acquisition rather than by any transformative merger, preserving its independence as a focused neuroscience company. Founded in 2012 by Herriot Tabuteau and taken public in 2015, the company began as a clinical-stage developer and built its structure by advancing internal candidates and acquiring or licensing individual assets, most notably the 2022 acquisition of SUNOSI rights from Jazz Pharmaceuticals, which added a commercial product, along with the 2025 Baergic Bio acquisition and the DeuteRx licensing deal. This approach has kept Axsome an independent, single-purpose central-nervous-system company rather than folding it into a larger organization or diversifying it beyond neuroscience. The resulting structure is a focused biopharmaceutical company organized into commercial medicines, a late-stage pipeline, early-stage programs and licensing partnerships, all concentrated in CNS conditions, with the founder still at the helm as chief executive and chair. That structural simplicity, an independent, founder-led neuroscience company assembled through internal work and targeted asset deals rather than mergers, keeps management attention and resources concentrated on the brain and nervous system, and it means Axsome's future structure will continue to evolve through the acquisition and licensing of individual CNS assets rather than through corporate combination, sustaining its identity as a specialized, independent neuroscience company.
Ownership History
Ownership History Analysis
Axsome's history traces a deliberate climb from a founder's clinical-stage venture to a commercial neuroscience company. Herriot Tabuteau founded and initially financed the company in 2012, took it public on Nasdaq in 2015, and spent its early years advancing central-nervous-system drug candidates through development. The pivotal transition came in 2022, when AUVELITY received approval for major depressive disorder, creating a commercial business, and the company acquired SUNOSI from Jazz Pharmaceuticals to add a second marketed medicine and build its commercial capabilities. Axsome then broadened its portfolio, launching the migraine treatment SYMBRAVO and acquiring pipeline assets including Baergic Bio and deuterated bupropion rights in 2025, and in 2026 it secured approval to expand AUVELITY into Alzheimer's disease agitation, a large underserved indication, all while Tabuteau remained chief executive and board chair. Generating about 638 million dollars of revenue, Axsome has become a growing commercial neuroscience company. Its history is that of a founder-led biopharmaceutical company that methodically progressed from clinical development into commercial sales, assembling a differentiated CNS portfolio through internal innovation and targeted asset acquisition, and whose next chapter depends on scaling its approved medicines and advancing its pipeline into a sustainably profitable, specialized neuroscience enterprise.
Ownership Explained
Axsome Therapeutics is a central-nervous-system biopharmaceutical company that has crossed from development into commercial sales, based in New York and traded on Nasdaq as AXSM. Founder Herriot Tabuteau, who started the company in 2012 and still serves as chief executive and board chair, holds about 4 percent of the shares, with the balance widely held by institutions including Vanguard, BlackRock and the biotech specialists Perceptive Advisors and Farallon. Roughly 925 employees supported about 638 million dollars of 2025 revenue drawn from a growing portfolio of approved medicines, AUVELITY for depression and Alzheimer's agitation, SUNOSI for excessive sleepiness, and SYMBRAVO for migraine, backed by a pipeline of investigational CNS treatments. The company remains founder-led as it scales its commercial business.
An Axsome share is a claim on a founder-built neuroscience company at the pivotal transition from a clinical-stage developer into a commercial enterprise. Unlike a pre-revenue biotech, Axsome now sells approved medicines and generates growing revenue, but it is still investing heavily to launch and expand those products and to advance a pipeline, so profitability remains a work in progress. Founder-chief-executive Herriot Tabuteau, holding a meaningful personal stake, drives a strategy of combining internal development with targeted acquisitions of CNS assets. What owners are backing is the successful commercialization of AUVELITY and its newer products, the value of an approved-drug portfolio in large neuropsychiatric markets, and pipeline optionality, a growth story that hinges on commercial execution and clinical success rather than any established earnings base.